$-0.10 EPS Expected for Actinium Pharmaceuticals, Inc. (ATNM); 3 Analysts Covering Standard Chartered PLC (SCBFF)

March 14, 2018 - By Pete Kolinski

Analysts expect Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) to report $-0.10 EPS on March, 15. The stock 1.20% or $0 during the last trading session, reaching $0.42. It is up 15.34% since March 14, 2017 and is downtrending. It has underperformed by 32.04% the S&P500.

Among 9 analysts covering Standard Chartered PLC (OTCMKTS:SCBFF), 3 have Buy rating, 3 Sell and 3 Hold. Therefore 33% are positive. Standard Chartered PLC had 10 analyst reports since September 22, 2015 according to SRatingsIntel. The rating was upgraded by Bank of America on Tuesday, January 17 to “Buy”. Credit Suisse initiated the stock with “Underperform” rating in Tuesday, November 29 report. Berenberg upgraded the shares of SCBFF in report on Thursday, January 14 to “Buy” rating. The stock of Standard Chartered PLC (OTCMKTS:SCBFF) earned “Neutral” rating by JP Morgan on Tuesday, February 21. RBC Capital Markets downgraded Standard Chartered PLC (OTCMKTS:SCBFF) on Monday, October 24 to “Underperform” rating. The firm has “Buy” rating given on Thursday, October 8 by Goldman Sachs. The company was downgraded on Monday, October 12 by Investec. The rating was downgraded by Citigroup on Thursday, November 5 to “Neutral”. Investec upgraded the shares of SCBFF in report on Tuesday, September 22 to “Buy” rating. The stock has “Sell” rating by Credit Agricole on Friday, December 18. See Standard Chartered PLC (OTCMKTS:SCBFF) latest ratings:

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company has market cap of $33.63 million. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. It currently has negative earnings. The Company’s lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.

Investors sentiment decreased to 1.71 in Q3 2017. Its down 0.29, from 2 in 2017Q2. It worsened, as 5 investors sold Actinium Pharmaceuticals, Inc. shares while 3 reduced holdings. 10 funds opened positions while 6 raised stakes. 14.18 million shares or 237.86% more from 4.20 million shares in 2017Q2 were reported. Two Sigma Ltd Llc reported 17,745 shares stake. Dafna Management Ltd invested 0.12% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Raymond James Advisors has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). California Pub Employees Retirement System has 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Blackrock Incorporated invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Da Davidson & Com holds 48,000 shares. Bank Of America De holds 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 960 shares. Bank & Trust Of Montreal Can invested in 0% or 2,500 shares. Sabby Mngmt Limited Liability Co accumulated 2.43M shares. Art Ltd Liability Com holds 0% or 30,005 shares in its portfolio. Anson Funds Mngmt Limited Partnership has 1.02 million shares. Credit Suisse Ag has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Dowling & Yahnke Limited Liability Com has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). 172,300 are owned by Bridgeway Cap Mgmt. The Illinois-based Citadel Advsrs Ltd Com has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM).

Standard Chartered PLC provides various banking services and products in Asia, Africa, and the Middle East. The company has market cap of $36.29 billion. The firm operates in four divisions: Corporate & Institutional Banking, Private Banking, Commercial Banking, and Retail Banking. It has a 46.35 P/E ratio. It offers personal banking services, including savings and accounts; personal, instalment, or revolving loans; mortgages; credit cards; life, savings and retirement planning, health and medical, home, motor, and travel insurance products; investment advisory services; retail FX products; mutual funds; and employee banking services.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: